Finally, after years of poor quality and insufficient research in the field of complex regional pain syndrome (CRPS), the research community is taking a structured interest. There are several reasons for this interest: 1) the FDA’s inclusion of CRPS as a “rare disease,” and the protection and advantages that provides to pharma and device manufacturers in the form of “orphan drug status”; 2) the international acceptance of a uniform diagnostic criteria, called the Budapest Criteria; 3) the delphi development of a core research data scheme (COMPACT); and, of course 4) the lack of definitive treatment(s) for this horrorshow disease. There are many new randomized controlled trials/therapies for drugs and devices and the evolving development of research targeting in terms of sets and subsets of disease mechanism and appropriate outcomes/measurements for these sets—mechanism of disease matched to mechanism of intervention—to guide primary therapies. Thus, a thorough CRPS update is warranted and provided in this presentation.
Describe IASP criteria for complex regional pain syndrome
Describe the “Budapest” criteria for complex regional pain syndrome
List the effects of sympathetic and peptidergic nerve fibers on skin and immune cells